Emergent BioSolutions Inc - Company Profile
Powered by 
All the sales intelligence you need on Emergent BioSolutions Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Emergent BioSolutions Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Emergent BioSolutions Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Emergent BioSolutions Inc (Emergent) is a biopharmaceutical company focused on developing products to address medical needs and public health threats (PHTs). The company’s solutions help in addressing chemical, biological, radiological, travel health, emerging health crises, nuclear and explosives (CBRNE), emerging infectious diseases, and acute/emergency care. Its major products and services encompass a portfolio of vaccines, nasal sprays, therapeutics, drug-device combination products, and contract development and manufacturing services. The company’s pipeline products include zaire ebolavirus, raxibacumab for anthrax, and others. Emergent's products are utilized by federal and state leaders, community-based organizations, law enforcement, and first responders for applications such as opioid emergency preparedness and medical countermeasures against health threats like botulism, Ebola, smallpox, and anthrax. The company distributes its products in the US and Canada through its commercial sales forces and third-party distributors. Emergent is headquartered in Gaithersburg, Maryland, the US.
Headquarters
United States of America
Address
Suite 400, 300 Professional Drive, Gaithersburg, Maryland, 20879
Website
www.emergentbiosolutions.com
Telephone
1 240 6313200
No of Employees
900
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
EBS (NYSE)
Revenue (2024)
$742.9M
-28.8%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
127.6%
(2024 vs 2023)
Market Cap*
$427.2M
Net Profit Margin (2024)
XYZ
138.8%
(2024 vs 2023)
* As of and is in US$
Emergent BioSolutions Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| BioThrax - Anthrax Vaccine | Drug Substance Manufacturing | Anthrasil |
| ACAM2000 - Smallpox (Vaccinia) Vaccine | Process Development, Optimization | ACAM2000 |
| Anthrasil - Inhalational Anthrax | Analytical Development and Testing Services | BAT |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In June, the company secured a US$52.7 million contract from the Administration for Strategic Preparedness and Response at the US Department of Health and Human Services to supply ACAM2000 (Smallpox and Mpox (Vaccinia) Vaccine, Live) vaccine, ancillaries and diluent replacement lots for smallpox preparedness. |
| 2026 | Contracts/Agreements | In May, the company secured a US$64.5 million contract from the Administration for Strategic Preparedness and Response for BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)]. |
| 2026 | Regulatory Approval | In May, the company received regulatory approval from the Saudi Food and Drug Authority for ACAM2000 [Smallpox and Mpox (Vaccinia) Vaccine, Live] for the prevention of smallpox and mpox disease. |
Competitor Comparison
| Key Parameters | Emergent BioSolutions Inc | AbbVie Inc | Thermo Fisher Scientific Inc | Lonza Group Ltd | FUJIFILM Biotechnologies USA Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | Switzerland | United States of America |
| City | Gaithersburg | North Chicago | Waltham | Basel | Morrisville |
| State/Province | Maryland | Illinois | Massachusetts | Basel-Stadt | North Carolina |
| No. of Employees | 900 | 57,000 | 125,000 | 16,866 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Zsolt Harsanyi | Chairman | Executive Board | 2022 | 82 |
| Joseph C. Papa | Director; President; Chief Executive Officer | Executive Board | 2024 | 70 |
| Richard S. Lindahl | Chief Financial Officer; Executive Vice President | Senior Management | 2018 | 62 |
| Simon Lowry | Head - Research and Development; Chief Medical Officer | Senior Management | 2024 | 53 |
| Stephanie Duatschek | Chief Global Strategy and Franchise Development Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer